Top Guns From Daiichi Sankyo Take Positions on Ranbaxy Board

MUMBAI - Japanese drug maker Daiichi Sankyo has reorganized the board of directors of Ranbaxy, a company in which it acquired 63.92 percent equity for an investment of $4.5 billion. Ranbaxy CEO and Managing Director Malvinder Mohan Singh will assume an additional role as chairman in the newly structured board